TIGIT is a key inhibitory checkpoint receptor in lymphoma.
Journal for immunotherapy of cancer(2023)
Abstract
These results provide rationale for clinical investigation of TIGIT and PD-1 blockade in lymphomas, including DLBCL.
MoreTranslated text
Key words
key inhibitory checkpoint receptor
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined